|1.||Lebret, Thiery: 1 article (06/2015)|
|2.||Jinga, Viorel: 1 article (06/2015)|
|3.||Sinescu, Ioanel: 1 article (06/2015)|
|4.||Petkova, Lidiya: 1 article (06/2015)|
|5.||Hublarov, Oleg: 1 article (06/2015)|
|6.||Dutailly, Pascale: 1 article (06/2015)|
|7.||Rouanne, Mathieu: 1 article (06/2015)|
|8.||Kotsev, Rumen: 1 article (06/2015)|
|9.||Almeida, Paulo Roberto Carvalho de: 1 article (01/2015)|
|10.||Vasconcelos, Paulo Roberto Leitão de: 1 article (01/2015)|
|1.||Prostatic Neoplasms (Prostate Cancer)
06/01/2015 - "This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer."
08/01/2003 - "Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer."
06/01/2015 - "In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later). "
06/01/2015 - "Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer."
09/01/2013 - "This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer."
01/01/2001 - "Triptorelin pamoate 11.25 mg given in microgranules is a 3-month sustained-release administration form which appears to be safe and effective in advanced prostatic carcinoma. "
01/01/2001 - "Two different formulations of triptorelin pamoate 11.25 mg were assessed in 2 groups of 10 patients suffering from prostatic carcinoma. "
|3.||Weight Loss (Weight Reduction)
|4.||Hypogonadism (Hypergonadotropic Hypogonadism)
04/01/2004 - "In fact, we found that in a rabbit model of hypogonadotropic hypogonadism (induced by a single administration of the long-acting GnRH agonist triptorelin pamoate, 2.9 mg/kg), OT responsiveness was strongly reduced and was completely restored by estradiol valerate (3.3 mg/kg weekly), but not by testosterone enanthate (30 mg/kg weekly). "
|2.||Gonadotropin-Releasing Hormone (GnRH)
|4.||Aspirin (Acetylsalicylic Acid)
|5.||estradiol valerate (Delestrogen)
|6.||testosterone enanthate (Delatestryl)
|4.||Palliative Care (Palliative Medicine)